Limits...
CD44 expression in patients with combined hepatocellular cholangiocarcinoma.

Kim R, Kim SB, Cho EH, Park SH, Park SB, Hong SK, Chae G - Ann Surg Treat Res (2015)

Bottom Line: In ChC, the group that expressed CD44 showed earlier recurrence than the group that did not express CD44 (P = 0.040).The expression of cancer stem cell markers in ChC did not show a different pattern compared to that found in HCC.The expression of cancer stem cell marker CD44 was associated with poor prognosis in patients with ChC.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.

ABSTRACT

Purpose: Combined hepatocellular cholangiocarcinoma (ChC) is a rare type of primary liver cancer, which is thought to have a poorer prognosis than hepatocellular carcinoma (HCC). Cancer stem cells are associated with tumorigenesis, tumor progression, recurrence, metastasis, and poor prognosis in several malignancies including HCC. The aim of this study was to investigate the expression pattern of cancer stem cell markers in ChC and HCC, and to evaluate whether this pattern correlated to patient prognosis.

Methods: Thirteen patients who underwent curative hepatic resection for ChC and 13 patients who underwent curative hepatic resection for HCC (matched control cases) were included. Immunohistochemical staining for cancer stem cell markers (cytokeratin [CK]7, CK19, C-kit, cluster of differentiation [CD] 44, CD133, and epithelial cell adhesion molecule) was performed and clinical outcomes were analyzed retrospectively.

Results: There was no significant difference in cancer stem cell marker expression between ChC and HCC. In ChC, the group that expressed CD44 showed earlier recurrence than the group that did not express CD44 (P = 0.040).

Conclusion: The expression of cancer stem cell markers in ChC did not show a different pattern compared to that found in HCC. The expression of cancer stem cell marker CD44 was associated with poor prognosis in patients with ChC.

No MeSH data available.


Related in: MedlinePlus

Recurrence-free survival analysis between the CD44 expressed positive group and unexpressed group in ChC. The CD44 expressed group (solid line, n = 3) showed a significantly earlier recurrence than unexpressed group (dotted line, n = 10). ChC, combined hepatocellular cholangiocarcinoma; CD44, cluster of differentiation 44.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4481034&req=5

Figure 3: Recurrence-free survival analysis between the CD44 expressed positive group and unexpressed group in ChC. The CD44 expressed group (solid line, n = 3) showed a significantly earlier recurrence than unexpressed group (dotted line, n = 10). ChC, combined hepatocellular cholangiocarcinoma; CD44, cluster of differentiation 44.

Mentions: To identify the relationship between patient prognosis and cancer stem cell marker expression in ChC, we analyzed recurrence-free survival in 13 cases. The ChC subtype with stem cell features was not associated with a poorer prognosis than the classical type of ChC (P = 0.515). However, recurrence-free survival analysis of the expression of each cancer stem cell marker revealed that the CD44 positive group showed earlier recurrence than the CD44 negative group (P = 0.040) (Fig. 3). The recurrence-free survival time of the CD44 positive group was 4.4 ± 1.3 (mean ± standard deviation) months, whereas that of the CD44 negative group was 41.8 ± 14.4 months. There was no significant difference between the groups that were positive for other markers and the groups that were negative (Table 4).


CD44 expression in patients with combined hepatocellular cholangiocarcinoma.

Kim R, Kim SB, Cho EH, Park SH, Park SB, Hong SK, Chae G - Ann Surg Treat Res (2015)

Recurrence-free survival analysis between the CD44 expressed positive group and unexpressed group in ChC. The CD44 expressed group (solid line, n = 3) showed a significantly earlier recurrence than unexpressed group (dotted line, n = 10). ChC, combined hepatocellular cholangiocarcinoma; CD44, cluster of differentiation 44.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4481034&req=5

Figure 3: Recurrence-free survival analysis between the CD44 expressed positive group and unexpressed group in ChC. The CD44 expressed group (solid line, n = 3) showed a significantly earlier recurrence than unexpressed group (dotted line, n = 10). ChC, combined hepatocellular cholangiocarcinoma; CD44, cluster of differentiation 44.
Mentions: To identify the relationship between patient prognosis and cancer stem cell marker expression in ChC, we analyzed recurrence-free survival in 13 cases. The ChC subtype with stem cell features was not associated with a poorer prognosis than the classical type of ChC (P = 0.515). However, recurrence-free survival analysis of the expression of each cancer stem cell marker revealed that the CD44 positive group showed earlier recurrence than the CD44 negative group (P = 0.040) (Fig. 3). The recurrence-free survival time of the CD44 positive group was 4.4 ± 1.3 (mean ± standard deviation) months, whereas that of the CD44 negative group was 41.8 ± 14.4 months. There was no significant difference between the groups that were positive for other markers and the groups that were negative (Table 4).

Bottom Line: In ChC, the group that expressed CD44 showed earlier recurrence than the group that did not express CD44 (P = 0.040).The expression of cancer stem cell markers in ChC did not show a different pattern compared to that found in HCC.The expression of cancer stem cell marker CD44 was associated with poor prognosis in patients with ChC.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.

ABSTRACT

Purpose: Combined hepatocellular cholangiocarcinoma (ChC) is a rare type of primary liver cancer, which is thought to have a poorer prognosis than hepatocellular carcinoma (HCC). Cancer stem cells are associated with tumorigenesis, tumor progression, recurrence, metastasis, and poor prognosis in several malignancies including HCC. The aim of this study was to investigate the expression pattern of cancer stem cell markers in ChC and HCC, and to evaluate whether this pattern correlated to patient prognosis.

Methods: Thirteen patients who underwent curative hepatic resection for ChC and 13 patients who underwent curative hepatic resection for HCC (matched control cases) were included. Immunohistochemical staining for cancer stem cell markers (cytokeratin [CK]7, CK19, C-kit, cluster of differentiation [CD] 44, CD133, and epithelial cell adhesion molecule) was performed and clinical outcomes were analyzed retrospectively.

Results: There was no significant difference in cancer stem cell marker expression between ChC and HCC. In ChC, the group that expressed CD44 showed earlier recurrence than the group that did not express CD44 (P = 0.040).

Conclusion: The expression of cancer stem cell markers in ChC did not show a different pattern compared to that found in HCC. The expression of cancer stem cell marker CD44 was associated with poor prognosis in patients with ChC.

No MeSH data available.


Related in: MedlinePlus